Strongbridge Biopharma plc to Present at the Cantor Fitzgerald Global Healthcare Conference
September 18 2017 - 6:30AM
Strongbridge Biopharma plc, (Nasdaq:SBBP), a global
commercial-stage biopharmaceutical company focused on the
development and commercialization of therapies for rare diseases
with significant unmet needs, today announced that management
will present at the Cantor Fitzgerald Global Healthcare Conference,
taking place September 25-27, 2017 at
the InterContinental New York Barclay Hotel.
Matthew Pauls, president and chief executive officer
of Strongbridge Biopharma, will provide a corporate overview
on Monday, September 25 at 10:20 a.m. ET. The
presentation will be webcast live and archived on the “Events &
Presentations” page in the Investor section of the Company’s
website at www.strongbridgebio.com.
About Strongbridge Biopharma
Strongbridge Biopharma is a
commercial-stage global biopharmaceutical company focused on the
development and commercialization of therapies for rare diseases
with significant unmet needs. Strongbridge's first commercial
product is KEVEYIS® (dichlorphenamide), the first and
only FDA-approved treatment for hyperkalemic, hypokalemic, and
related variants of Primary Periodic Paralysis. KEVEYIS has orphan
drug exclusivity status in the U.S. through August 7, 2022. In
addition to establishing this neuromuscular disease franchise, the
Company has a clinical-stage pipeline of therapies for rare
endocrine diseases. Strongbridge's lead compounds include RECORLEV™
(levoketoconazole), a cortisol synthesis inhibitor currently being
studied for the treatment of endogenous Cushing's syndrome, and
veldoreotide, a next-generation somatostatin analog being
investigated for the treatment of acromegaly, with potential
additional applications in Cushing's syndrome and neuroendocrine
tumors. Both RECORLEV and veldoreotide have received orphan
designation from the U.S. Food and Drug Administrationand
the European Medicines Agency. For more information,
visit www.strongbridgebio.com.
Contacts:
Corporate and Media Relations Elixir Health
Public Relations Lindsay Rocco +1 862-596-1304
lrocco@elixirhealthpr.com
Investor RelationsU.S.:The Trout Group Marcy
Nanus +1 646-378-2927 mnanus@troutgroup.com
Europe:First HouseMitra Hagen Negård+47 21 04
62 19strongbridgebio@firsthouse.no
USA 900 Northbrook Drive Suite 200 Trevose,
PA 19053 Tel. +1 610-254-9200 Fax. +1 215-355-7389
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From Apr 2024 to May 2024
Strongbridge Biopharma (NASDAQ:SBBP)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Strongbridge Biopharma PLC (NASDAQ): 0 recent articles
More News Articles